Beelen D - Search Results

1

Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Socie G, Kroeger N, Blaise D, Veelken H, Bermudez A, Or R, Lioure B, Beelen D, Fegueux N, Hamladji RM, Nagler A, Mohty M. Kharfan-Dabaja MA, et al. Among authors: beelen d. Leuk Res. 2015 Sep;39(9):933-7. doi: 10.1016/j.leukres.2015.04.009. Epub 2015 Apr 24. Leuk Res. 2015. PMID: 26003666

2

Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG).

De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lönnqvist B, Beelen D, Ferrant A, Gmür J, et al. De Witte T, et al. Among authors: beelen d. Br J Haematol. 1990 Feb;74(2):151-5. doi: 10.1111/j.1365-2141.1990.tb02558.x. Br J Haematol. 1990. PMID: 2180469 Clinical Trial.

3

Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia.

Beelen DW, Quabeck K, Graeven U, Sayer HG, Mahmoud HK, Schaefer UW. Beelen DW, et al. Blood. 1989 Oct;74(5):1507-16. Blood. 1989. PMID: 2790182 Free article.

4

Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome.

Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B, Schaefer UW. Beelen DW, et al. Blood. 1995 May 15;85(10):2981-90. Blood. 1995. PMID: 7742558 Free article.

5

A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.

Elmaagacli AH, Beelen DW, Schaefer UW. Elmaagacli AH, et al. Among authors: beelen dw. Bone Marrow Transplant. 1997 Dec;20(12):1045-55. doi: 10.1038/sj.bmt.1701026. Bone Marrow Transplant. 1997. PMID: 9466277

6

Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.

Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW. Elmaagacli AH, et al. Among authors: beelen dw. Bone Marrow Transplant. 1998 Jan;21(2):159-66. doi: 10.1038/sj.bmt.1701056. Bone Marrow Transplant. 1998. PMID: 9489633

7

Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.

Elmaagacli AH, Beelen DW, Trenn G, Schmidt O, Nahler M, Schaefer UW. Elmaagacli AH, et al. Among authors: beelen dw. Bone Marrow Transplant. 1999 Apr;23(8):771-7. doi: 10.1038/sj.bmt.1701672. Bone Marrow Transplant. 1999. PMID: 10231138

8

The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation.

Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW. Elmaagacli AH, et al. Among authors: beelen dw. Bone Marrow Transplant. 2000 Jan;25(1):91-6. doi: 10.1038/sj.bmt.1702095. Bone Marrow Transplant. 2000. PMID: 10654021

9

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.

Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Löffler H, Staib P, Heyll A, Seifarth W, Saussele S, Fonatsch C, Gassmann W, Ludwig WD, Hochhaus A, Beelen D, Aul C, Sauerland MC, Heinecke A, Hehlmann R, Wörmann B, Hiddemann W, Büchner T. Lengfelder E, et al. Among authors: beelen d. Leukemia. 2000 Aug;14(8):1362-70. doi: 10.1038/sj.leu.2401843. Leukemia. 2000. PMID: 10942230 Clinical Trial.

10

Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia.

Flasshove M, Meusers P, Schütte J, Noppeney R, Beelen DW, Sohrab S, Roggenbuck U, Kemmeries G, Brittinger G, Seeber S, Scheulen ME. Flasshove M, et al. Among authors: beelen dw. Ann Hematol. 2000 Oct;79(10):533-42. doi: 10.1007/s002770000193. Ann Hematol. 2000. PMID: 11100742

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

414 results

Search Page

Filters